

ALLERGAN INC
Form DEFA14A
October 09, 2014

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

October 9, 2014

Date of Report (Date of Earliest Event Reported)

ALLERGAN, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware	1-10269	95-1622442
(State of Incorporation)	(Commission File Number)	(IRS Employer
		Identification Number)

2525 Dupont Drive

Irvine, California 92612

(Address of Principal Executive Offices) (Zip Code)

(714) 246-4500

(Registrant's Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition.

On October 9, 2014, Allergan, Inc. issued a press release providing an update on earnings per share and sales expectations. A copy of the press release is furnished as Exhibit 99.1 hereto.

Item 8.01. Other Events

The disclosure under Item 2.02 is incorporated herein by reference

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

- 99.1 Press Release dated October 9, 2014; Allergan Provides Update on Earnings Per Share and Sales Expectations

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALLERGAN, INC.

Date: October 9, 2014

By: /s/ Matthew J. Maletta

Name: Matthew J. Maletta

Title: Vice President,
Associate General Counsel and Secretary

Exhibit Index

Exhibit	Description of Exhibit
99.1	Press Release dated October 9, 2014; Allergan Provides Update on Earnings Per Share and Sales Expectations